Absci Corporation filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the period ended September 30, 2026, disclosing financial results, risk factors, and operational updates for the third quarter of fiscal year 2026.

Key Highlights

  • Shares outstanding: The registrant had 172,745,810 shares of $0.0001 par value common stock outstanding as of October 30, 2026.
  • Filer classification: Absci is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under the Exchange Act.
  • Continued losses expected: According to the filing, the company "has incurred significant losses since inception" and expects to incur losses in the future.
  • Capital needs disclosed: The filing states the company "will need to raise additional capital" to fund operations and nonclinical and clinical development of its internally developed programs.
  • Platform dependency: The filing identifies the company as "substantially dependent on the successful application" of its Integrated Drug Creation platform to identify, design, and advance product candidates.
  • Reporting period: The quarterly period covered is July 1, 2026 through September 30, 2026.

Absci's Q3 2026 Filing: Operations, Risks, and Capital Position

Absci Corporation (NASDAQ:ABSI), a Delaware-incorporated biopharmaceutical company headquartered at 18105 SE Mill Plain Blvd, Vancouver, WA 98683, filed its Form 10-Q for the quarterly period ended September 30, 2026. As of October 30, 2026, the company reported 172,745,810 shares of common stock outstanding at a par value of $0.0001 per share. The filing covers unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025.

The filing discloses that the company has incurred significant losses since inception and expects this to continue. It further states that the company will need to raise additional capital to fund operations and to expand the capabilities of its Integrated Drug Creation platform, cautioning that if it is "unable to raise additional capital on terms acceptable to us or at all," it may not be able to continue developing its internally developed programs or compete successfully. The filing notes that biologic drug development "is inherently uncertain" and that no assurance exists that any product candidates will achieve regulatory approval or become viable commercial products.

Among the key operational risks disclosed, the filing identifies dependence on third-party contract research organizations for nonclinical and clinical studies, reliance on a limited number of suppliers for laboratory equipment and materials, and competitive pressures in the markets for Integrated Drug Creation platform technology. The company also notes that its "partnership strategy significantly depends on the eventual approval and commercialization of product candidates developed under our partnerships," over which it may have no control regarding clinical development plans or regulatory strategy. The filing includes a Risk Factors section spanning Part II, Item 1A.

What Was Disclosed

Absci Corporation filed its Form 10-Q for the quarter ended September 30, 2026, reporting 172,745,810 shares outstanding as of October 30, 2026, disclosing continued operating losses, capital needs, and risks tied to its Integrated Drug Creation platform and drug development programs.